At the world’s largest oncology meeting, which concluded this week, researchers presented new findings that suggest that the timing, combination and duration of immunotherapy, as well as the order in which drugs are given, may have an even greater impact on skin cancer patient outcomes than previously understood.

The American Society of Clinical Oncology (ASCO) Annual Meeting , held May 30 through June 3 in Chicago, brought together tens of thousands of cancer professionals. This year’s event featured more than 200 sessions, including presentations from academic institutions and advocacy groups worldwide.

Among presentations related to skin cancer, the oral abstract sessions, which generally feature important, practice-changing, or newsworthy research, highlighted how melanoma is treat

See Full Page